No data to show
OTCM
CLCS
Market cap15mUSD
Jul 22, Last price
0.35USD
1D
-10.23%
1Q
9.41%
Jan 2017
-22.20%
IPO
-77.41%
Name
Cell Source Inc
Chart & Performance
P/E
—
P/S
—
EPS
—
Div Yield, %
—
Shrs. gr., 5y
6.52%
Rev. gr., 5y
%
Revenues
0k
Net income
-5m
L+2.97%
CFO
-2m
L-25.20%
Earnings
Jul 28, 2025
Profile
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. The company's lead product is the Veto Cell immune system management technology, which is an immune tolerance biotechnology that enables the selective blocking of immune responses. Its Veto Cell technology is used in various applications, including treatment of lymphoma, leukemia, and multiple myeloma through facilitation of the stem cell transplantation acceptance, as well as treatment of end stage kidney disease and other non-malignant organ diseases, and various cancers and non-malignant diseases. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | 4,183 | 4,175 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (4,183) | (4,175) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | (4,183) | (4,175) | |||||||
Net income | (5,321) 2.97% | (5,168) -24.37% | |||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | 800 | ||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | 9,254 | 7,904 | |||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | 9,232 | 7,682 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (2,348) | (3,139) | |||||||
CAPEX | 1 | ||||||||
Cash from investing activities | |||||||||
Cash from financing activities | 2,147 | 3,268 | |||||||
FCF | (2,852) | (2,842) | |||||||
| Balance | |||||||||
Cash | 22 | 223 | |||||||
Long term investments | |||||||||
Excess cash | 22 | 223 | |||||||
Stockholders' equity | (41,626) | (36,308) | |||||||
Invested Capital | 35,268 | 31,451 | |||||||
ROIC | |||||||||
ROCE | 65.79% | 85.95% | |||||||
| EV | |||||||||
Common stock shares outstanding | 37,786 | 34,836 | |||||||
Price | 0.85 -33.62% | ||||||||
Market cap | 29,611 -30.17% | ||||||||
EV | 37,294 | ||||||||
EBITDA | (4,183) | 285,295,825 | |||||||
EV/EBITDA | 0.00 | ||||||||
Interest | 1,049 | 992 | |||||||
Interest/NOPBT | |||||||||